Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
The USPSTF changed the low-dose aspirin recommendations for cardiovascular disease prevention in April 2022 by suggesting patients over age 60 without history of CVD should not take it and people 40-60 should only take it if there are other risk factors.

VIDEO: USPSTF official discusses new low-dose aspirin recommendations

Michael J. Barry, MD, vice chair of the U.S. Preventive Services Task Force, gave Cardiovascular Business an overview of the new recommendations.

Thumbnail

Combining certain BP medications with NSAIDs linked to kidney damage—acetaminophen seen as a safer option

A team of researchers used computer science and mathematics to study the "triple whammy" of diuretics, RAS inhibitors and NSAIDs.

Thumbnail

How the science behind COVID-19 vaccines could transform care for heart attack patients

A technique seen in the Pfizer-BioNTech and Moderna COVID-19 vaccines may be able to help heart cells repair themselves, according to new research out of the Netherlands. 

mavacamten

FDA approves mavacamten for obstructive hypertrophic cardiomyopathy

The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

Statin reduces risk for non-obstructive CAD patients but no significant risk reduction for aspirin

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

Thumbnail

USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

fda recall Accupril pfizer

FDA announces another recall of common hypertension medication due to potential cancer risk

The new recall includes five lots of medications distributed from December 2019 to April 2022. Similar products were also recalled back in March for the same reason.

FDA announces new insulin recall due to potential labeling issue

The recall is focused on a single batch distributed from December 2021 to March 2022.

Displaying 225 - 232 of 290

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup